Sensei Biotherapeutics Inc (SNSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has a cash flow conversion efficiency ratio of -0.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.59 Million) by net assets ($23.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sensei Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Sensei Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SNSE total debt and obligations for a breakdown of total debt and financial obligations.
Sensei Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
0.008x |
|
High Peak Royalties Ltd
AU:HPR
|
0.021x |
|
Greenland Acquisition Corp
NASDAQ:GTEC
|
0.118x |
|
Ecomiam SA
PA:ALECO
|
-0.357x |
|
Ginting Jaya Energi
JK:WOWS
|
0.061x |
|
M.P.Evans Group
LSE:MPE
|
0.128x |
|
Clemondo Group AB (publ)
ST:CLEM
|
0.018x |
|
GULLBERG+JANSSON AB
F:9D7
|
0.050x |
Annual Cash Flow Conversion Efficiency for Sensei Biotherapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Sensei Biotherapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see SNSE market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also off… Read more